Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

Disclosed herein are methods for otoprotection against platinum-based antineoplastic agents by administering a thiosulfate salt to a subject in need thereof. Typically, the thiosulfate salt is administered to the subject scheduled to be administered a platinum-based antineoplastic agent within 4 hours. Alternatively, the thiosulfate salt is administered within 7 hours after the administration of a platinum-based neoplastic agent.

This disclosure relates to uses of deoxycholic acid, salts, or derivatives thereof in managing bacterial infections and compositions related thereto. In certain embodiments, this disclosure relates to methods of treating or preventing a bacterial infection comprising administering an effective amount of a deoxycholic acid, salts, or derivatives thereof to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating or preventing Streptococcus pneumoniae comprising administering an effective amount of a deoxycholic acid salt to a subject in need thereof.

The present disclosure relates to methods for treating a variety of diseases and/or ameliorating pain by administering to the ear canal of a subject a composition.

The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of an COCH associated condition.

A composition having nanoparticles having lipids; a polysaccharide coating, an active agent and iron oxide. The active agent can be ciprofloxacin or fluocinolone. A method of treatment of ear disease or ear infection including the administration of a pharmaceutical formulation comprising nanoparticles and magnetically pushing or pulling the nanoparticles to a treatment site.

This application relates to a pharmaceutical composition for anti-inflammation, including a probiotic and an antibiotic, and a method of preventing or treating inflammation by using the same. In one aspect, the method includes locally administrating a probiotic and an antibiotic to an inflamed area of a subject.

Methods for introducing a gene into a cell of the inner ear, e.g., a cochlear or vestibular cell, e.g., a hair cell, e.g., for therapy, that include the use of exosomes associated with one or more adeno-associated viral (AAV) particles.

An earplug (1) for administering a fluid agent into an ear canal is provided. The earplug (1) comprises a first part (10) adapted for insertion in the ear canal. The first part comprises an elongated member (11) having a chamber (12) for containing the fluid agent, the chamber (12) having at least one outlet (13) at a proximal end (14) of the elongated member (11); and a malleable member (17) disposed laterally of the elongated member (11). The earplug (1) further comprises a second part (20) comprising a piston (21). The piston (21) has a first end (22) which is insertable in the elongated member (11), and a second end (23) which has a push member (24). The piston (21) is displaceable from a first position (A) distally of the chamber (12) to a second position (B) within the chamber (12), such that the fluid agent is injected from the chamber (12) through the outlet (13) into the ear canal.

Presented herein are techniques for localized release of systemically circulating therapeutic substances, which combine many of the advantages of systematic and localized administration, while eliminating many of the associated drawbacks. More specifically, in accordance with the techniques presented herein, an electro-responsive biomaterial is systemically administered to a recipient of an electrically-stimulating implantable medical device. The electro-responsive biomaterial comprises a therapeutic substance that is only activated (e.g., released) in the presence of an electromagnetic field generated by the electrically-stimulating implantable medical device.